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Abstract
Background: Mucopolysaccharidoses are heritable, metabolic diseases caused by deficiency in an
activity of one of specific lysosomal enzymes involved in degradation of mucoplysaccharides
(glycosaminoglycans). Among many medical problems of patients with mucopolysaccharidoses,
there are frequent episodes of diarrhea of unknown etiology.
Case presentation: A girl, diagnosed enzymatically for mucopolysaccharidosis type I (deficiency
of α -L-iduronidase) at the age of 3 years and 9 months, was investigated until the age of 5 years
and 4 months. Frequent loose stools and episodes of diarrhea, often accompanied by vomiting,
were encountered. Detailed microbiological analyses were performed and atypical microbial
infections (most often enetropathogenic Escherichia coli, but also other species, like Pseudomonas
aeruginosa or Staphylococcus aureus, as well as adenoviruses) of the digestive tract were found in
most severe diarrhea episodes. Often, isolations of pathogenic bacterial strains from stools of the
investigated patient suffering from diarrhea were not obvious during the first screening, and only
detailed microbiological studies, including re-isolation of colonies, gave the results of isolation of
particular pathogenic strains (especially in the case of enetropathogenic E. coli).
Conclusion: We conclude that atypical microbial infections of digestive tract may contribute
significantly to diarrhea in mucopolysaccaridosis patients. Since isolated strains were not typical and
their isolation was often possible only after detailed investigation (not during a standard screening),
such atypical microbial infections of digestive tract of mucopolysaccharidosis patients could be
usually overlooked to date. Importantly, these atypical infections could be effectively treated with
antimicrobial agents.
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Background
Mucopolysaccharidoses (MPS) are rare genetic diseases,
inherited in an autosomal recessive manner (except MPS
type II, which is X-linked) [1]. Each MPS is caused by defi-
ciency in an activity of one of specific lysosomal enzymes
involved in degradation of mucoplysaccharides (gly-
cosaminoglycans, GAGs). When activity of such an
enzyme is impaired, GAGs are not destroyed but their
accumulate in lysosomes of virtually every cell of the body
as well as outside of cells [1,2]. Depending on the kind of
a deficient enzyme, several types of mucopolysaccaridosis
can be distinguished [3].
Cells of MPS patients do not perform properly, which
leads to progressive damage throughout the body (mainly
connective tissue), including the heart, respiratory system,
bones, joints and, in some cases, central nervous system
[1,3]. In most cases the disease is fatal, however, predic-
tion of its severity and clinical progress is usually difficult,
even when biochemical and genetic data are available [4].
Among many medical problems, MPS patients suffer from
frequent episodes of loose stools and diarrhea. Although
mechanisms of other symptoms of MPS are known to
some extend, the cause of diarrhea remains obscure [1,3].
One might speculate that it could be a defect in the auto-
nomic nervous system caused by storage of gly-
cosaminoglycans, and resultant abnormal motility of the
bowel would cause the diarrhea. However, few evidences
can support such a hypothesis. Therefore, we have investi-
gated factor(s) that might contribute to this problem of
MPS patients. Here, a case report is presented, in which a
MPS I patient was investigated, however, it is worth men-
tioning that diarrhea is also a common problem for MPS
patients of other types. MPS I is caused by a defect in the
gene coding for α -L-iduronidase [5]. We found that epi-
sodes of diarrhea were accompanied by atypical microbial
infections that could be treated by antimicrobial agents.
Recently, a specific treatment of MPS I became available,
since recombinant human α -L-iduronidase (Aldura-
zyme®, laronidase) has been shown to be effective [6,7].
During three months of treatment of the patient with
Aldurazyme, no diarrhea episodes occurred, strongly sug-
gesting that previous episodes results indirectly from MPS
rather than from putative, MPS-independent, enhanced
susceptibility of the patient to microbial infections of
intestine.
Case presentation
A girl, diagnosed enzymatically for MPS I (McKusick's
OMIM (MPS I, Hurler syndrome, Scheie syndrome):
25280) at the age of 3 years and 9 months, was investi-
gated until the age of 5 years and 4 months. Genetic anal-
ysis (performed by us) indicated that one allele of the α -
L-iduronidase gene contains a mutation causing a com-
mon Q70X truncation in the enzyme amino acid
sequence. Further studies (performed at Consorzio Genet-
ica Moleculare Umana, Monza, Italy, supervised by Prof.
Andrea Biondi and coordinated by Genzyme Co.) con-
firmed the presence of this allele and indicated that the
second mutation is an in frame deletion of three base
pairs (codon 349), resulting in the loss of aspartic acid res-
idue (∆ 349). The investigated MPS I patient suffered,
between other symptoms characteristic for this disease,
from frequent diarrhea or loose stools, often accompa-
nied by vomiting. No obvious contacts with persons suf-
fering from intestinal infections, including family
members (who also had no documented chronic or often
diarrhea), were noticed shortly before or during these epi-
sodes. During the most severe episodes of diarrhea,
detailed microbiological analyses of stools were per-
formed. The patient was never treated with antibiotics
before stool collection, thus, results of microbiological
assays were not affected by such a treatment. Bacterial,
viral or fungal infections were detected in all these analy-
ses (Table 1).
Isolation and preliminary analyses for identification and
characterization of bacteria, viruses and fungi were per-
formed using S-F selenium, blood agar, CNA, McConkey,
SS, XLD, Sabouraud, Kligler and Singer, and BHI media
(purchased from Becton Dickinson, Biomed or Bimex).
Detailed analyses were performed using biochemical
assay kits ID GN 32 (BioMerieux), EN-COCCUStest
(Lachema) and ATB ID 32 C (BioMerieux), and immuno-
logical tests (kits purchased from Immunomed and
BioMarieux). The microbiological assays were performed
according to the semi-quantitative method, described pre-
viously [8]. Non-enteropathogenic strains of Escherichia
coli, strains of Enterococcus faecalis and small amounts of
other bacteria belonging to Enterobacteriaceae were con-
sidered as normal aerobic bacterial flora. Identification of
enteropathogenic E. coli strains was performed using a
specific latex-immunological assay (purchased from
Biomex). In this assay, 10 randomly chosen E. coli colo-
nies (classified on the basis of microbiological and bio-
chemical tests described above) were streak onto nutrient
agar plates, and following 18 h incubation at 35°C bacte-
ria were tested immunologically using the Biomex kit. The
O antigens (characteristic for enteropathogenic E. coli
strains but not for other strains of this bacterium), were
detectable in this assay, and corresponding strains, bear-
ing particular antigens, were divided into following
groups: group A (antigens O26, O55, O111, O127 and
O142), group B (antigens O86, O119, O124, O125,
O126 and O128) and group C (antigens O18, O25, O44
and O114).
As summarized in Table 1, all viral infections were caused
by adenoviruses, and tests were negative after diarrhea was
finished. Most bacterial infections were atypical.BMC Pediatrics 2005, 5:9 http://www.biomedcentral.com/1471-2431/5/9
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Enteropathogenic Escherichia coli belonging to group A or,
more frequently, to group C, was detected in over 50% of
positive tests. These bacteria may cause diarrhea in
infants, but they are very rare agents causing intestinal
problems in older children and adults, thus the tests for
detection of these strains are usually not performed in
routine studies if the patient is not an infant [9,10]. Pseu-
domonas aeruginosa, Staphylococcus aureus and Candida albi-
cans  were also detected, though significantly less
frequently than E. coli group C. These species can be
detected also in stools of healthy persons. Thus, in our
assays, they were considered potential etiological agents
only when they dominated quantitatively over other
microbes treated as physiological flora, and the domi-
nance was significant. In fact, during the episode at the age
of 28 months (Table 1), P. aeruginosa was the only bacte-
rium isolated from the stool sample. Although no antibi-
otic therapy was applied in this case (due to problems
with efficacy of treatment of P. aeruginosa infections with
antibiotics), the symptoms of diarrhea disappeared and
normalization of the intestinal flora was achieved after
using tablets containing Lactobacillus rhamnosus. This
strongly suggests a significant contribution of the P. aeru-
ginosa  infection to diarrhea. At the age of 45 months,
when the patient suffered from a very severe diarrhea and
vomiting (Table 1), apart from adenoviruses, C. albicans
was detected in large quantities in stool samples, and large
amounts of Haemophilus parainfluenzae, Streptococcus viri-
dans  and  Neiserria  sp. were isolated from oral cavity.
Although S. viridans and Neiserria are considered as a part
of normal bacterial flora of oral cavity in infants, their
abundance, together with that of H. parainfluenzae was
accompanied with significant depletion of the rest of
physiological flora. During the episode of diarrhea at the
age of 56 months (Table 1), apart from isolation of enter-
opathogenic E. coli, severe depletion of physiological flora
and presence of large quantities of S. aureus and C. albicans
was found. The enteropathogenic E. coli strain might be
the major bacterial contributor to this infection as treat-
ment with furazidin (which is generally not used for treat-
ment of S. aureus infections) and fluconazole (an
antifungal agent) was effective.
It is worth mentioning that isolations of pathogenic bac-
terial strains from stools of the investigated patient suffer-
ing from diarrhea were often not obvious during the first
screening, especially in the case of enteropathogenic E.
coli. Only detailed microbiological studies, including re-
isolation of colonies, gave the results of isolation of par-
ticular pathogenic strains (summarized in Table 1). We
suppose that this could be the explanation of the fact that
atypical microbial infections of digestive tract of MPS
patients were usually overlooked to date. On the other
hand, these infections apparently caused diarrhea. In
most episodes accompanied by isolation of bacterial
infection, drug sensitivities were determined and antibiot-
ics were used accordingly (Table 1). After this treatment,
diarrhea was resolved and pathogenic bacteria were not
Table 1: History of the most severe diarrhea events caused by microbial infections of intestine of the MPS I patient
Age of the patienta Detected pathogenic microbial 
strain(s)
Antimicrobial agent(s) used Special remarks
11 months E. coli (group C) Trimethoprim and 
sulphamethoxazole
Severe diarrhea and vomiting, metabolic 
acidosis, hospitalization and i.v. rehydration 
required
21 months (1 y. 9 mo.) E. coli (group C) Cefuroxime Initially applied trimethoprim and 
sulphamethoxazole did not give a 
therapeutic effect
27 months (2 y. 3 mo.) E. coli (group A) Nifuroxazide None
28 months (2 y. 4 mo.) P. aeruginosa None Tablets containing Lactobacillus rhamnosus 
were used to normalize intestinal flora
29 months (2 y. 5 mo.) E. coli (group C) Furazidin None
45 months (3 y. 9 mo.) Adenoviruses, C. albicans (in 
addition, H. parainfluenzae, S. viridans 
and Neiserria sp. were isolated from 
oral cavity)
Cefuroxime, fluconazole, 
trimethoprim and 
sulphamethoxazole
Very severe diarrhea and vomiting, severe 
dehydration and electrolyte depletion, 
metabolic acidosis, severe stomatitis. 
Hospitalization and parenteral nutrition 
required
49 months (4 y. 1 mo.) Adenoviruses None None
50 months (4 y. 2 mo.) E. coli (group C) Furazidin, trimethoprim and 
sulphamethoxazole
Severe diarrhea, hospitalization and i.v. 
rehydration required
54 months (4 y. 6 mo.) Adenoviruses None None
55 months (4 y. 7 mo.) E. coli (group C) Furazidin None
56 months (4 y. 8 mo.) E. coli (group C), S. aureus, C. albicans Furazidin, fluconazole None
a Age of the patient is provided in months as well as in years (y.) and months (mo.) in parenthesesBMC Pediatrics 2005, 5:9 http://www.biomedcentral.com/1471-2431/5/9
Page 4 of 5
(page number not for citation purposes)
detected in stools. Similar results were obtained after ther-
apy with an antifungal drug, when C. albicans was
detected (data not shown).
Intestinal flora was normal when tested in periods of nor-
mal stools (microbiological tests were performed 5 times
during such periods as control experiments; data not
shown). This provides an additional support for the
hypothesis that isolated pathogenic microbial strains
caused diarrhea, rather than the patient was a carrier of an
atypical bacterial flora.
The patient was treated with Aldurazyme (laronidase;
recombinant human α -L-iduronidase), by weekly infu-
sions of 100 U per 1 kg of body weight, during last three
months of the study, and no episodes of diarrhea occurred
during that period. This indicates that episodes of severe
diarrhea, listed in Table 1, resulted directly or indirectly
from accumulation of GAGs, rather than from a putative,
unrelated to MPS I, enhanced susceptibility of the patient
to microbial infections of intestine.
Conclusion
On the basis of the results presented in this report, we sug-
gest that microbial infections of intestine may contribute
significantly to episodes of diarrhea in MPS patients. Is it
clear that influence of other factors and agents, for exam-
ple those resulting from dietary incompliance, cannot be
excluded. Nevertheless, it seems clear that the most severe
diarrhea events in the MPS I patient were caused by micro-
bial infections, as when pathogenic bacteria or fungi were
isolated, antibiotic treatment always resulted in normali-
zation of stools. One may speculate that GAGs, which
accumulate in MPS patients' digestive tract, could provide
a favorable medium for microbial growth. Under such
conditions, any disturbance in the content of intestinal
flora would make an overgrowth of a pathogenic strain
significantly more likely than in a healthy person. Finally,
accumulated GAGs might also impair production and/or
action of IgA, a class of antibodies predominating in an
intestine [11,12], which would make a patient more sen-
sitive to microbial infections. One might consider that in
MPS patients, diarrhea arises directly from GAG accumu-
lation and partial dysfunction of autonomous nervous
system. Although we cannot exclude such a possibility,
the arguments listed above indicate that atypical micro-
bial infections of digestive tract may contribute signifi-
cantly to diarrhea in these patients.
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